<DOC>
	<DOCNO>NCT02219724</DOCNO>
	<brief_summary>This first-in-human , Phase 1 , open-label , multicenter , dose-escalation study design evaluate safety , tolerability , pharmacokinetics MOXR0916 administer intravenously participant locally advance metastatic solid tumor progress available standard therapy standard therapy proven ineffective intolerable , consider inappropriate . This study consist screen period , initial treatment period , re-treatment period ( participant discontinue MOXR0916 demonstration prolong clinical benefit ) , post-treatment follow-up period . Participants enrol two stage : dose-escalation stage expansion stage . The planned duration study approximately 3 year .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics MOXR0916 Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologic documentation locally advance , recurrent metastatic incurable solid malignancy progress available standard therapy standard therapy proven ineffective intolerable , consider inappropriate Confirmed availability representative tumor specimens paraffin blocks/unstained slide Measurable disease per RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic end organ function For female participant childbearing potential , agreement use highly effective form ( ) contraception continue use 6 month last dose MOXR0916 Any anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy , within 3 week prior initiation study treatment ( hormonal therapy gonadotropinreleasing hormone agonist antagonists prostate cancer palliative radiotherapy great ( &gt; ) 2 week prior Cycle 1 , Day 1 allow ) Eligibility base prior treatment immunomodulatory agent depend mechanistic class drug cohort participant consider Adverse event prior anticancer therapy resolve Grade less equal ( &lt; /= ) 1 except alopecia endocrinopathy manage replacement therapy Primary central nervous system ( CNS ) malignancy , untreated/active CNS metastases Leptomeningeal disease Malignancies disease study within 5 year History autoimmune disease History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia , evidence active pneumonitis screen chest compute tomography ( CT ) scan ; history radiation pneumonitis radiation field ( fibrosis ) permit Positive test human immunodeficiency virus infection Active hepatitis B active hepatitis C Severe infection within 4 week sign symptom infection within 2 week prior Cycle 1 Prior allogeneic bone marrow transplantation prior solid organ transplantation Significant cardiovascular disease Known clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>